Bleeding in advanced CKD patients on antithrombotic medication - A critical appraisal

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Patients with advanced chronic kidney disease (CKD) have elevated bleeding risks, particularly when treated for coronary artery disease (CAD), atrial fibrillation, or venous thromboembolism.
• These patients are often excluded from clinical trials, leading to a lack of evidence-based recommendations for antithrombotic therapy in high bleeding risk scenarios.

Purpose of the Study:

• To review current evidence and identify gaps in managing antithrombotic therapy for advanced CKD patients with CAD and/or atrial fibrillation.
• To evaluate bleeding risk assessment tools and propose management strategies, including dose adjustments and therapeutic approaches.

Main Methods:

• Literature review focusing on advanced CKD patients requiring antithrombotic treatment.
• Analysis of existing European Society of Cardiology (ESC) Guidelines and bleeding risk scores.
• Discussion of clinical scenarios involving antiplatelet and oral anticoagulation therapies.

Main Results:

• Significant evidence gaps exist for antithrombotic treatment recommendations in advanced CKD patients.
• Current bleeding risk scores may have limitations in strength, reliability, and usefulness for this population.
• There is a need for clear algorithms to balance bleeding and thrombosis risks.

Conclusions:

• Improved management strategies are needed for advanced CKD patients undergoing antithrombotic therapy.
• Further research and guideline development are crucial to address the specific needs of this high-risk group.
• Clinicians require better tools and guidance for risk assessment and therapeutic decision-making.